Phibro Animal HealthPAHC
Recorded

Phibro Animal Health 2027 Q1 Earnings Call

Review the key takeaways and the transcript of this earnings call.

PeriodQ1 2027Duration25 minParticipants7

Transcript

Preview the first fifteen paragraphs, organized by speaker.

Operator

Hello, everyone. Thank you for joining us, and welcome to Phibro Animal Health Corporation to host webcast and conference call on first quarter results. After today's prepared remarks, we will host a question-and-answer session. If you would like to ask a question, please press star one to raise your hand. To withdraw your question, press star one again. I will now hand the conference over to Glenn David, Chief Financial Officer. Glenn, please go ahead. Thank you, Kendra.

Glenn DavidCFO

Good day, and welcome to the Phibro Animal Health Corporation earnings call for our fiscal first quarter ending September 30th, 2026. My name is Glenn David, and I am the Chief Financial Officer of Phibro Animal Health Corporation. I am joined on today's call by Dani Bendheim, President and Chief Executive Officer, and Larry Miller, Chief Operating Officer. Also on today's call is Patrick Rodriguez, our Treasurer and new Head of Investor Relations. Welcome, Patrick, to the call, and I'm going to turn things over to you.

Patrick RodriguezTreasurer and Head of Investor Relations

Thank you, Glenn, and I look forward to interacting with all of you in the coming months. Today, we will cover financial performance for our first quarter and provide financial guidance for our fiscal year ending June 30th, 2027. At the conclusion of our remarks, we will open the lines for your questions. I would also like to remind you that we're providing a simultaneous webcast of this call on our website, pahc.com. Also, on the Investors section of our website, you will find copies of the earnings press release and quarterly Form 10-Q, as well as the transcript and slides discussed and presented on this call. Our remarks today will include forward-looking statements, and actual results could differ materially from those projections. For a list and description of certain factors that would cause results to differ, I refer you to the Forward-Looking Statements section in our earnings press release.

Patrick RodriguezTreasurer and Head of Investor Relations

Our remarks include references to certain financial measures which were not prepared in accordance with generally accepted accounting principles, or US GAAP. I refer you to the Non-GAAP Financial Information section in our earnings press release for a discussion of these measures. Reconciliations of these non-GAAP financial measures to the most directly comparable US GAAP measures are included in the financial tables that accompany the earnings press release. We present our results on a GAAP basis and on an adjusted basis. Our adjusted results exclude acquisition-related items, unusual non-operational or non-recurring items, including stock-based compensation, other income expenses as separately reported in the consolidated statements of operations, including foreign currency losses, gains, net, income taxes related to pre-tax income adjustments, and unusual or non-recurring income tax items. Now, let me introduce our President and Chief Executive Officer, Dani Bendheim, to share his opening remarks.

Dani BendheimPresident and CEO

Donny? Thanks, Patrick, and good morning, everyone.

Dani BendheimPresident and CEO

Patrick, welcome to your first call. Fiscal 2027 is off to a good start. Sales grew 6% to $386.8 million, and adjusted EBITDA grew 4% to $64.3 million. We did that against a tough comparison, coming off a very strong first quarter a year ago. Let me spend a few minutes on what drove the quarter and how we're thinking about the rest of the year. Our two non-animal health segments did a lot of the heavy lifting this quarter. Performance Products grew 16%, and Mineral Nutrition grew 17%. I want to spend a moment on Mineral Nutrition because I think it's part of our business that tends to get overlooked. Part of this quarter's growth reflects higher prices for zinc, copper, and other underlying commodities, and those prices obviously move up and down.

Dani BendheimPresident and CEO

Over time, we've also been moving this business toward the higher-margin, faster-growing parts of the market, including plant nutrition, dairy, and pet food. Customers in these markets are asking for more on ingredient sourcing, quality, consistency, and technical support. Those requirements play to our strengths because of the investments we've made in talent, facilities, and processes. That's a credit to the Mineral Nutrition management team, who have been patient in building those relationships and capabilities. We expect the business to continue growing in these higher-margin areas. In animal health, sales grew 3%, about right where we planned. MFAs were up 6%, with good demand in North America and Asia, and continued growth in ethanol processing aids. That's net of a $5.2 million decline in virginiamycin in Brazil.

Dani BendheimPresident and CEO

Nutritional specialties and vaccines were each down 2%, mostly on softer poultry purchases in North America and Brazil, plus some timing in Asia. People are still buying chicken. The pressure is on the producer side. Based on reports from several large protein companies over the last couple of weeks, U.S. chicken supply was up a little over 2%, which outpaced demand and pushed prices down, and producer margins have come off last year's unusually strong levels. In Brazil, exports have been strong, but the domestic market was soft. The number of birds being raised is a healthy number, and that ultimately is what matters most for us. When margins tighten, customers look harder at every input cost and purchase. A producer who counts cost per pound can see what our products return.

Dani BendheimPresident and CEO

Some customers trim spending and cut inventory, and we saw a bit of that in our poultry sales this quarter, particularly in nutritional specialties and vaccines. The underlying demand for chicken is there, and we do well when it is. We see this pullback as temporary, and we expect it to normalize over the course of this fiscal year. Our forecast still has both of these product lines growing in the mid to high single digits for the year. Animal health adjusted EBITDA in the quarter was down 1% from last year, though better than we had planned. Part of that reflects costs that moved from the first quarter into the second. On virginiamycin in Brazil, the transition period ended in October. Our conversations with regulators about therapeutic claims are ongoing, and now that the Brazilian election has passed, we're hopeful we'll see some movement.

Dani BendheimPresident and CEO

We haven't built any further virginiamycin sales in Brazil into this year's numbers. If an approval comes, it's upside. On the full year, we expect protein demand to continue growing, but producer profitability is likely to stay soft in the near term, and recent trade and disease disruptions in protein markets add to the pressure. That's reflected in our outlook, so we're keeping our fiscal 2027 guidance where it was. Net sales of $1.5 billion-$1.6 billion, adjusted EBITDA of $258 million-$268 million, and adjusted diluted EPS of $3.41-$3.59. Two other updates. First, the closure of our Chicago Heights plant remains on schedule. Production should wind down in the summer and early fall of 2027, with those products moving to our other Phibro plants and to contract manufacturers. Second, cash. We were cash positive in the quarter, but I am not satisfied.

Dani BendheimPresident and CEO

We're carrying more inventory than we need, and bringing it down this year is a priority for me and for our whole team. Better cash conversion gives us more flexibility on debt, on investment, and on returns to shareholders. So, a good quarter with plenty of work still ahead. With that, let me turn the call over to Glenn.

Glenn DavidCFO

Thanks, Tony. Starting with our Q1 performance on slide four. Consolidated net sales for the quarter ended September 30th, 2026, were $386.8 million, reflecting an increase of $22.9 million, or a 6% increase over the same quarter one year ago. The Animal Health segment grew 3%, while Mineral Nutrition grew at 17%, and Performance Products grew at 16%. Turning to the bottom line, net income for the first quarter was $29.5 million. That's an increase of $3 million, or about 11%, compared to $26.5 million in the same quarter last year. Let me walk you through the key drivers. Operating income was down $1.6 million, as higher SG&A more than offset the improvement we delivered in gross profit. Below the operating line, we saw several favorable items.

Glenn DavidCFO

First, net interest expense declined $0.8 million, reflecting lower interest rates and higher interest income, including interest received on our IEEPA tariff recoveries. Second, foreign currency was a $0.4 million gain this quarter compared to a $2.0 million loss a year ago, a favorable swing of $3.3 million. Third, income tax expense was $0.5 million lower. Taken together, these items more than offset the lower operating income and drove the $3 million improvement in net income for the quarter. After making our standard adjustments to GAAP results, including acquisition-related items, foreign currency losses, and certain one-off items, the first quarter adjusted EBITDA increased $2.4 million, or 4% versus prior year.

Glenn DavidCFO

Adjusted net income of $32.4 million increased $2.5 million, primarily due to higher gross profit, lower interest expense, and a lower adjusted effective income tax rate, partially offset by higher adjusted SG&A due to higher employee-related costs. Moving to segment-level financial performance on slide five. The Animal Health segment posted $293 million net sales for the quarter, an increase of $9.6 million, or 3% versus the same quarter prior year. Within the Animal Health segment, we reported MFAs and other net sales increase of $11.3 million, or an increase of 6%, due to increased demand for certain of our MFAs in North America and Asia, and higher sales of ethanol processing aids, partially offset by a decrease of $5.2 million in virginiamycin sales in Brazil, attributable to regulatory developments in the country.

Glenn DavidCFO

Nutritional specialty net sales decreased $1.1 million, or 2%, due to lower poultry demand in North America and decreased aquaculture demand in South America, partially offset by higher overall demand in China and higher companion animal sales. Vaccine net sales decreased by $0.6 million, or 2%, due to lower demand for poultry products in Brazil and lower sales in Asia, partly due to timing, offset by higher swine demand in North America and higher sales of adjuvant products. Animal Health adjusted EBITDA decreased $1 million due to higher SG&A, offsetting higher gross profit from increased sales. Moving on to first quarter financial performance for our other business segments on slide six.

FULL TRANSCRIPT

Continue the full translated transcript in StockNow.

Log in to unlock every statement, the English original, and speaker-by-speaker history.

Log in for the full transcript

Other earnings calls that day

View calls from this day